Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma
This article was originally published in PharmAsia News
Executive Summary
Following through on a goal to expand operations in one of the world's fastest growing markets, Nycomed AS confirmed Nov. 1 that it is beefing up its Chinese presence through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma
You may also be interested in...
Takeda's China Development Remains In CRO Hands
Takeda said there is "difficulty" in determining how a China research unit would fit into its global R&D program.
A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed
Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.
A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed
Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.